CD19 and CD32b Differentially Regulate Human B Cell Responsiveness

Abstract

B cell activation is regulated by a variety of signals. CD19 positively regulates B cell activation, augmenting signals delivered through the BCR complex. In contrast, CD32b contains an ITIM and negatively regulates BCR signaling. Importantly, there are drugs currently in clinical trials and preclinical development that cross-link CD32b to molecules within the BCR complex. We wanted to address how single engagement versus cotargeting these molecules affects human B cell function. When B cells from healthy individuals were activated by signals that mimic a T cell response (IL-21 costimulation), ligation of CD32b, but not CD19, inhibited B cell expansion and plasma cell (PC) differentiation. In contrast, when B cells were activated through TLR, anti-CD19, but not anti-CD32b, blunted the response. However, when both CD19 and CD32b were coengaged by a bispecific anti-CD19×CD32b Ab, both types of stimuli were potently inhibited. Cross-linking CD19 with CD32b also inhibited Ab-independent functions of B cells, such as HLA upregulation, cytokine production, and the ability of B cells to prime CD4+ T cells. Finally, although cross-linking CD19 and CD32b inhibited PC differentiation of primary B cells, it did not alter Ig production from pre-established PCs. These data elucidate the mechanism by which a complex set of signals determines the fate of B cell responsiveness. Although signals through CD19 influence TLR-driven activation, CD32b impacts the magnitude of the response following IL-21 costimulation. Therefore, simultaneous targeting of multiple surface molecules may be a necessary approach to comprehensively modulate B cell activation in vivo.

Extinct type of human parvovirus B19 persists in tonsillar B cells

“…The CD32 receptor plays an important role in the downregulation of B-cell responses and its deficiency or reduced expression correlates to prolonged humoral or autoimmune reactivity3334. Analogously, B19V-related arthropathies are allegedly due to IgG deposition1 and this virus has been proposed to play a role in triggering or exacerbating autoimmune diseases35.…”

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics

“…Furthermore, we introduced the mutation L234F [31] which, when combined with the S239C mutation, should hypothetically abrogate all Fc effector functions.…”

Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties

“…[1][2][3][4][5][6][7][8][9][10][11][12] Bispecific molecules described thus far can be divided into five classes based on their molecular format: 1) BsAb with IgG1-like structure, which are monovalent for each antigen; 2) BsAb prepared by appending binding domains to the IgG, which are bivalent for each antigen; 3) BsAb prepared using antibody fragments, which are monovalent for each antigen and often lack the Fc region; 4) bispecific fusion proteins, which are formed of an antibody fragment genetically linked to a protein to add additional functionality or specificity; and 5) bispecific conjugates, which are prepared by chemical conjugation of antibody fragments. While some such bispecific molecules have demonstrated manufacturing robustness, in vivo drug-like properties, suitable pharmacokinetics (PK) and efficacy have been achieved, platforms that yield multifunctional bispecific antibodies with different spatial configurations and flexibility suitable for a variety of target and disease applications are still needed.…”